or Try an Advanced Search...

    Technical Analysis for CVAC - CureVac N.V.

    Grade Last Price % Change Price Change
    F 2.54 -4.87% -0.13
    CVAC closed down 4.87 percent on Friday, November 15, 2024, on 2.38 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical CVAC trend table...
    Date Alert Name Type % Chg
    MACD Bearish Signal Line Cross Bearish 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Stochastic Reached Oversold Weakness 0.00%
    BB Squeeze Ended Range Expansion 0.00%
    Below Lower BB Weakness 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    20 DMA Resistance Bearish -4.87%
    Bollinger Band Squeeze Range Contraction -4.87%
    Older End-of-Day Signals for CVAC ...

       Recent Intraday Alerts

    Alert Time
    Down 1 ATR 2 days ago
    60 Minute Opening Range Breakdown 2 days ago
    Down 5% 2 days ago
    5x Volume Pace 2 days ago
    Down 3% 2 days ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    CVAC Chart by TradingView
    Basic chart:

    Profile

    CureVac N.V. Description

    CureVac B.V., a clinical-stage biopharmaceutical company, engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102 that is in a Phase I clinical trial for the treatment of various types of solid tumors; and CV7202, which is investigating in a Phase I clinical trial for vaccination against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase I clinical trial. The company has collaboration and license agreements with GlaxoSmithKline Biologicals SA, Genmab B.V., Boehringer Ingelheim GmbH, and Eli Lilly and Company; development and option agreements with Arcturus Therapeutics, Inc., Acuitas Therapeutics Inc., and CRISPR Therapeutics AG; and a development and intellectual property agreement with Tesla Grohmann Automation GmbH. CureVac B.V. was founded in 2000 and is headquartered in Tübingen, Germany.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Pharmaceutical Solid Tumors Acid Health Care Coronavirus Vaccination CRISPR Rabies Arcturus Therapeutics Genmab

    Is CVAC a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 15 Where are they now? 4 biotechs that soared then crashed during the pandemic
    Nov 13 CureVac NV (CVAC) Q3 2024 Earnings Call Highlights: Strong Financial Performance and Strategic ...
    Nov 12 CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript
    Nov 12 CureVac reports Q3 results
    Nov 12 CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
    Nov 12 Earnings Scheduled For November 12, 2024
    Nov 7 CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
    Nov 4 CureVac names former Cardior CFO Axel Sven Malkomes as new CFO
    Nov 4 CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
    Nov 4 CureVac to Present at the 12th International mRNA Health Conference
    See more CVAC news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.28
    52 Week Low 2.215
    Average Volume 462,541
    200-Day Moving Average 3.22
    50-Day Moving Average 2.93
    20-Day Moving Average 2.78
    10-Day Moving Average 2.78
    Average True Range 0.16
    RSI (14) 35.06
    ADX 18.31
    +DI 12.96
    -DI 23.91
    Chandelier Exit (Long, 3 ATRs) 2.54
    Chandelier Exit (Short, 3 ATRs) 2.99
    Upper Bollinger Bands 2.95
    Lower Bollinger Band 2.60
    Percent B (%b) -0.18
    BandWidth 12.44
    MACD Line -0.06
    MACD Signal Line -0.05
    MACD Histogram -0.0114
    Fundamentals Value
    Market Cap 568.77 Million
    Num Shares 224 Million
    EPS -1.58
    Price-to-Earnings (P/E) Ratio -1.61
    Price-to-Sales 18.27
    Price-to-Book 1.18
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.80
    Resistance 3 (R3) 2.82 2.75 2.76
    Resistance 2 (R2) 2.75 2.68 2.74 2.74
    Resistance 1 (R1) 2.64 2.64 2.61 2.63 2.73
    Pivot Point 2.57 2.57 2.55 2.56 2.57
    Support 1 (S1) 2.47 2.50 2.43 2.45 2.35
    Support 2 (S2) 2.40 2.46 2.39 2.34
    Support 3 (S3) 2.29 2.40 2.32
    Support 4 (S4) 2.28